Are there alternatives to cosentyx with similar effectiveness?

What alternatives exist for Cosentyx?

Cosentyx (secukinumab) works by targeting interleukin-17A to reduce inflammation in conditions such as plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. Similar alternatives fall into the same or nearby IL-17 and IL-23 pathways.

How do other IL-17 inhibitors compare?

Taltz (ixekizumab) and Bimzelx (bimekizumab) also block IL-17. Taltz shows comparable skin clearance rates in psoriasis trials, while Bimzelx covers both IL-17A and IL-17F. Taltz and Cosentyx have similar rates of upper respiratory infections and candida infections.

Can IL-23 inhibitors match Cosentyx performance?

Skyrizi (risankizumab), Tremfya (guselkumab), and Ilumya (tildrakizumab) target upstream IL-23. These agents produce PASI 90 responses in 70-80% of patients at 16-52 weeks. They tend to require less frequent dosing than Cosentyx and have lower candida risk.

What happens if Cosentyx fails?

Patients who do not respond to Cosentyx can switch to a different mechanism, such as TNF inhibitors (Humira, Enbrel) or JAK inhibitors (Xeljanz, Rinvoq). Switching between IL-17 inhibitors after failure is less likely to succeed than switching across classes.

Why are companies challenging this patent?

Novartis holds patents covering secukinumab until at least 2032. Biosimilar challenges began in 2024, but none have launched yet. DrugPatentWatch.com reports ongoing inter partes review proceedings against several Cosentyx patents.